Covered recipient · General Payments record
NINA T FOMBUH
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$994.12
- Reported across 34 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $517.36 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $126.88 | 1 |
| Novo Nordisk AS | $113.42 | 6 |
| PFIZER INC. | $82.04 | 4 |
| Insulet Corporation | $51.86 | 1 |
| Astellas Pharma US Inc | $33.64 | 1 |
| Acerta Pharma LLC | $27.45 | 1 |
| Gilead Sciences, Inc. | $27.25 | 1 |
| Organon LLC | $20.41 | 1 |
| GlaxoSmithKline, LLC. | $19.96 | 1 |
| Abbott Laboratories | $14.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $14.45 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125346407 | CMS |
| Astellas Pharma US Inc | $33.64 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139486368 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.45 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104570012 | CMS |
| Gilead Sciences, Inc. | $27.25 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133672984 | CMS |
| GlaxoSmithKline, LLC. | $19.96 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116298342 | CMS |
| Insulet Corporation | $51.86 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116802512 | CMS |
| Novo Nordisk Inc | $23.59 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100582988 | CMS |
| Novo Nordisk Inc | $19.19 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100453468 | CMS |
| Novo Nordisk Inc | $19.75 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100543132 | CMS |
| Novo Nordisk Inc | $16.29 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100493035 | CMS |
| Novo Nordisk Inc | $16.45 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100265460 | CMS |
| Novo Nordisk Inc | $18.15 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100580924 | CMS |
| Organon Llc | $20.41 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136299220 | CMS |
| Otsuka America Pharmaceutical, Inc. | $126.88 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119072256 | CMS |
| PFIZER INC. | $19.60 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131818154 | CMS |
| PFIZER INC. | $19.86 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131825438 | CMS |
| PFIZER INC. | $23.03 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131825514 | CMS |
| PFIZER INC. | $19.55 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131801532 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.